ETHERNA IMMUNOTHERAPIES
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.
ETHERNA IMMUNOTHERAPIES
Industry:
Biotechnology Health Care Medical Device Therapeutics
Founded:
2013-01-01
Address:
Jette, Brussels Hoofdstedelijk Gewest, Belgium
Country:
Belgium
Website Url:
http://www.etherna.be
Total Employee:
11+
Status:
Active
Contact:
+32 3 369 17 40
Total Funding:
111.78 M USD
Technology used in webpage:
LetsEncrypt Apple Mobile Web Clips Icon Domain Not Resolving Apache Nginx Google Maps JsDelivr Cloudflare JS CDN JS ShareThis
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Advisors List
Current Employees Featured
Founder
Investors List
Fund+
Fund+ investment in Series B - eTheRNA immunotherapies
Novalis LifeSciences
Novalis LifeSciences investment in Series B - eTheRNA immunotherapies
Life Sciences Partners
Life Sciences Partners investment in Series B - eTheRNA immunotherapies
Omega Funds
Omega Funds investment in Series B - eTheRNA immunotherapies
Grand Pharma
Grand Pharma investment in Series B - eTheRNA immunotherapies
Kenneth Chien
Kenneth Chien investment in Series B - eTheRNA immunotherapies
PMV
PMV investment in Series B - eTheRNA immunotherapies
European Commission
European Commission investment in Grant - eTheRNA immunotherapies
Novalis LifeSciences
Novalis LifeSciences investment in Series B - eTheRNA immunotherapies
BNP Paribas Private Equity
BNP Paribas Private Equity investment in Series B - eTheRNA immunotherapies
Official Site Inspections
http://www.etherna.be Semrush global rank: 4.87 M Semrush visits lastest month: 1.81 K
- Host name: linweb513.webhosting.be
- IP address: 5.134.6.103
- Location: Gouvy Belgium
- Latitude: 50.186
- Longitude: 5.9392
- Timezone: Europe/Brussels
- Postal: 6670
More informations about "eTheRNA immunotherapies"
Who we are - etherna
At etherna, we have the skills and technologies to provide our partners with top-notch support in their development & manufacturing needs to acquire nucleic acid-based therapeutics and vaccines. We have an expansive portfolio of …See details»
Management team - etherna
At etherna, we have the skills and technologies to provide our partners with top-notch support in their development & manufacturing needs to acquire nucleic acid-based therapeutics and vaccines. We have an expansive portfolio of …See details»
etherna immunotherapies - Crunchbase Company …
Organization. etherna immunotherapies . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... etherna’s mission is to be a technology leader in the development of nucleic …See details»
etherna - LinkedIn
Etherna | 12,148 followers on LinkedIn. Advancing RNA Medicine. Together. | www.etherna.be | www.ethernamanufacturing.com | Driving discovery and solving challenges for partners across LNP formulation and RNA chemistry | www.etherna.be | www.ethernamanufacturing.com We are an RNA technology company, with over 30 years’ experience, offering professional partnership …See details»
Etherna | IIC UGent
Etherna is an mRNA technology platform company with fully integrated capabilities including mRNA construct design and optimization, coupled with specialized expertise in designing and manufacturing customized lipid nanoparticles (cLNP) formulations tailored for the prevention and treatment of various pathological states, providing end-to-end solutions for next generation …See details»
eTheRNA - At.Las
ETheRNA immunotherapies is a clinical-stage Belgian biotech company applying mRNA based immunotherapies for the treatment of cancer and infectious diseases. eTheRNA was established in January 2013 as a spin-off company …See details»
eTheRNA Company Profile 2025: Valuation, Funding
When was eTheRNA founded? eTheRNA was founded in 2013. Where is eTheRNA headquartered? eTheRNA is headquartered in Niel, Belgium. What is the size of eTheRNA? eTheRNA has 115 total employees. What industry is …See details»
etherna - wetenschapsparkuantwerpen.be
Etherna is developing world-class mRNA immunotherapies for the treatment of cancer and infectious diseases. etherna uses messenger RNA to unleash and enhance a patient's immune response against a tumour or infectious agents. Research shows that this approach results in long-term clinical remission in cancer patients and protective immunity ...See details»
About - etherna
Etherna and Hasselt University announce autoimmune mRNA therapeutics research collaboration; Shelly West joins etherna as Business Development Director US; Recent Comments. No comments to show. Archives. January 2025; December 2024; July 2024; May 2024; April 2024; February 2024; December 2023; October 2023; June 2023;See details»
Etherna N.V. - Life-Sciences-Europe.com
Oct 17, 2023 BIO (US) (Biotechnology Innovation Organization, formerly Biotechnology Industry Organization) EuropaBio aisbl – the European Association of Bioindustries; BioIndustry Association (BIA) (GB) ... eTheRNA immunotherapies NV is developing immunotherapy and vaccine products for the treatment of cancer and infectious disease from its mRNA ...See details»
Millions in funding and new board members for mRNA company …
Aug 24, 2022 The mRNA technologies company eTheRNA has raised €39 million ($38.7 million) in series B2 financing. Belgium-based eTheRNA will use the money to expand investment in its integrated mRNA technology platform and further pursue its new initiatives for a partnership-driven business strategy.See details»
Bernard Sagaert - etherna - LinkedIn
I am a CEO at etherna, a biotech company that develops mRNA-based platforms to enable… · Experience: etherna · Education: Vlerick Business School · Location: St-Katelijne-Waver · 500+ connections on LinkedIn. View Bernard Sagaert’s profile on LinkedIn, a professional community of 1 billion members.See details»
Belgium's eTheRNA gets EU grant to develop mRNA cancer vaccines
Jan 10, 2025 Belgian immunotherapy firm eTheRNA has received a €6.9 million grant from the European Commission to accelerate clinical development of mRNA therapies for hard-to-treat cancers.See details»
Our culture - etherna
At etherna, we have the skills and technologies to provide our partners with top-notch support in their development & manufacturing needs to acquire nucleic acid-based therapeutics and vaccines. We have an expansive portfolio of intellectual property and know-how, particularly on customizable Lipid Nano Particles (cLNPs), supported by RNA chemistry and process …See details»
eTheRNA Company Profile - Office Locations, Competitors, …
ETheRNA has 5 employees across 4 locations and $66.27 m in total funding,. See insights on eTheRNA including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Will you be part of it? - etherna
Etherna provides research and manufacturing excellence by teaming up with highly skilled scientists, researchers and technical experts who are recognized for their contributions to the industry. We acquired substantial intellectual property and know-how over the years that support our exceptional leadership in mRNA and LNP innovation.See details»
ETHERNA - VUB TechTransfer
ETheRNA has secured the financial resources required to initiate the clinical validation of the in vivo off-the-shelf TriMix product, to continue the development of the ex vivo TriMix product and to optimize its existing mRNA manufacturing activities. eTheRNA has established a preferential research collaboration with the VUB, in particular with the LMCT team of Prof. Kris Thielemans …See details»
Technology partnering - etherna
Co-development of customized LNPs for a specific payload and application combining etherna’s expertise, suite of experimental tools, and proprietary ionizable lipid libraries with your disease and target knowledge. To drive discovery and solve challenges for our partners, enabling them to deliver cost-effective, ...See details»
etherna Announces Strategic Multi-Target Collaboration with …
Jan 9, 2025 About etherna etherna is a leading RNA technology company headquartered in Niel, Belgium and Boston, USA, with decades of experience in the field. Specializing in customizable Lipid Nanoparticles ...See details»
News Archives - etherna
Jan 9, 2025 Niel, Belgium and Boston, USA, January 9, 2025 – etherna immunotherapies NV (“etherna”), a technology platform leader pioneering mRNA and lipid-based nanoparticle (LNP) technologies, announces a strategic collaboration with Dropshot Therapeutics (“Dropshot”). ... Dr Owen Kaluwa, World Health Organization, concluded: “ The mRNA ...See details»